Dabrowska, Agata, <br/><br/>
FDA Risk Evaluation and Mitigation Strategies (REMS) :  description and effect on generic drug development  / 
 Food and Drug Administration Risk Evaluation and Mitigation Strategies (REMS) 
Agata Dabrowska. 
 - [Library of Congress public edition]. 
 - 1 online resource. 
 - Report / Congressional Research Service ;  R44810 .
 - CRS report ;  R44810. .
<br/><br/> The CRS report home page provides access to all versions published since 2018 in accordance with P.L. 115-141.  CRDP Program record. 
<br/><br/>Report includes bibliographical references. 
<br/><br/><label>LCCN: </label>2018253160 
<br/><br/><label>Subjects--Corporate Names: </label><br/>United States. Food and Drug Administration. 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Generic drugs.<br/>Pharmaceutical industry--United States.<br/>Pharmaceutical industry--Materials management--United States.
<br/><br/><label>GPO Item No.: </label>0807-A-07 (online) 
<br/><br/><label>Gov. Doc. Class. No.: </label>LC 14.23:R 44810/